Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

计划入组 90 人 · 首次发布于 2019 年 5 月 10 日

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

计划入组 350 人 · 首次发布于 2021 年 2 月 12 日

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer

计划入组 50 人 · 首次发布于 2024 年 3 月 15 日

Nadofaragene firadenovec-vncg(Adstiladrin)

in situ autologous dendritic cell therapy (liver cancer)

Bladder Cancer(Biomics Biotechnologies)

TATA MEMORIAL HOSPITAL

India

TATA MEMORIAL CENTRE

India

bioAffinity Technologies

United States

EMA Grants Conditional Marketing Authorization for ImmunityBio's ANKTIVA in Bladder Cancer

UroGen Pharma's UGN-102 Shows Promise in Bladder Cancer Treatment, Faces Market Cautiousness

Theralase Technologies Advances Bladder Cancer Treatment with Promising Phase II Trial Results